TY - JOUR
T1 - Nociplastic pain
T2 - towards an understanding of prevalent pain conditions
AU - Fitzcharles, Mary Ann
AU - Cohen, Steven P.
AU - Clauw, Daniel J.
AU - Littlejohn, Geoffrey
AU - Usui, Chie
AU - Häuser, Winfried
N1 - Funding Information:
SPC is supported by a grant from the US Department of Defense, Uniformed Services University, Department of Physical Medicine & Rehabilitation, Musculoskeletal Injury Rehabilitation Research for Operational Readiness (HU00011920011), which paid for the figures; and has consulted for Avanos, Persica, Scilex and Sorrento, and SPR Therapeutics. DJC reports grants from Aptinyx, Daiichi Sankyo, Eli Lilly, Intec Pharma, and Pfizer; personal fees from Aptinyx, Nix Patterson, Pfizer, Samumed, Theravance, Tonix, Williams & Connolly, and Zynerba; has consulted for Aptinyx, Eli Lilly, Pfizer, Samumed, and Tonix, outside the submitted work; and has received research funding from Aptinyx. WH received reimbursement for travel and accommodation by Bioevents (a congress organiser) for co-organising a conference on controversies on cannabis-based medicines in both 2018 and 2019. All other authors declare no competing interests.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/5/29
Y1 - 2021/5/29
N2 - Nociplastic pain is the semantic term suggested by the international community of pain researchers to describe a third category of pain that is mechanistically distinct from nociceptive pain, which is caused by ongoing inflammation and damage of tissues, and neuropathic pain, which is caused by nerve damage. The mechanisms that underlie this type of pain are not entirely understood, but it is thought that augmented CNS pain and sensory processing and altered pain modulation play prominent roles. The symptoms observed in nociplastic pain include multifocal pain that is more widespread or intense, or both, than would be expected given the amount of identifiable tissue or nerve damage, as well as other CNS-derived symptoms, such as fatigue, sleep, memory, and mood problems. This type of pain can occur in isolation, as often occurs in conditions such as fibromyalgia or tension-type headache, or as part of a mixed-pain state in combination with ongoing nociceptive or neuropathic pain, as might occur in chronic low back pain. It is important to recognise this type of pain, since it will respond to different therapies than nociceptive pain, with a decreased responsiveness to peripherally directed therapies such as anti-inflammatory drugs and opioids, surgery, or injections.
AB - Nociplastic pain is the semantic term suggested by the international community of pain researchers to describe a third category of pain that is mechanistically distinct from nociceptive pain, which is caused by ongoing inflammation and damage of tissues, and neuropathic pain, which is caused by nerve damage. The mechanisms that underlie this type of pain are not entirely understood, but it is thought that augmented CNS pain and sensory processing and altered pain modulation play prominent roles. The symptoms observed in nociplastic pain include multifocal pain that is more widespread or intense, or both, than would be expected given the amount of identifiable tissue or nerve damage, as well as other CNS-derived symptoms, such as fatigue, sleep, memory, and mood problems. This type of pain can occur in isolation, as often occurs in conditions such as fibromyalgia or tension-type headache, or as part of a mixed-pain state in combination with ongoing nociceptive or neuropathic pain, as might occur in chronic low back pain. It is important to recognise this type of pain, since it will respond to different therapies than nociceptive pain, with a decreased responsiveness to peripherally directed therapies such as anti-inflammatory drugs and opioids, surgery, or injections.
UR - http://www.scopus.com/inward/record.url?scp=85106595095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106595095&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)00392-5
DO - 10.1016/S0140-6736(21)00392-5
M3 - Review article
C2 - 34062144
AN - SCOPUS:85106595095
SN - 0140-6736
VL - 397
SP - 2098
EP - 2110
JO - The Lancet
JF - The Lancet
IS - 10289
ER -